BPC-157 has been observed to interact with the nitric oxide (NO) system and to upregulate growth hormone receptor expression in fibroblast cultures
The trade-off is pharmacokinetic: oral delivery subjects the peptide to stomach acid (pH roughly 1.5-2.0 fasting) and proteolytic enzymes including pepsin and pancreatic proteases before any absorption can occur
Your physician can assess whether dose optimization, combination therapy, or alternative treatment strategies are appropriate
Abbott is identified as a leading player in the market, supported by its strong portfolio of advanced nutritional supplements including protein shakes, digestive health products, and glucose management solutions, continuous innovation in GLP1 companion formulations, and global presence across home consumption, clinical nutrition, and diabetes care programs.
The role of diet alongside supplementation No supplement, Replenza or otherwise, can compensate for a poor diet during GLP-1 therapy